Antihypertensives: Global Markets to 2023
Report Scope:
The current report offers a detailed analysis of the antihypertensive drug market. The study includes a discussion of antihypertensive drugs prescribed for lowering the high blood pressure and for the treatment of pulmonary arterial hypertension (PAH). The report excludes drugs used in the treatment of ocular hypertension. The market size includes both branded and generic drugs.
The report highlights the current and future market potential of antihypertensive drugs and provides a detailed analysis of the competitive environment, regulatory scenario, patent analysis, pipeline analysis, drivers, restraints, opportunities and trends in the market. The report also covers market projections through 2023, as well as market shares for key market players.
The report details market shares of antihypertensive drugs based on drug class and geography. Based on drug class, the market is segmented into ACE inhibitors (angiotensin-converting enzyme inhibitors), ARBs (angiotensin II receptor blockers), beta blockers, calcium channel blockers, diuretics, combination drugs, and others (a segment that includes direct renin inhibitors, alpha blockers, PDE-5 inhibitors, stimulators of soluble guanylate cyclase, endothelin receptor antagonists, vasodilators, and prostacyclin receptors).
The market is segmented by geography into the following regions: North America, Europe, Asia-Pacific, South America, and the Middle East and Africa. The report presents detailed analyses of major countries such as the U.S., Canada, Mexico, Germany, the U.K. France, Spain, Italy, Japan, China and India. For market estimates, data is provided for 2017 as the base year, with forecasts for 2018 through 2023. Estimated values are based on drug manufacturers’ total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.
Report Includes:
The current report offers a detailed analysis of the antihypertensive drug market. The study includes a discussion of antihypertensive drugs prescribed for lowering the high blood pressure and for the treatment of pulmonary arterial hypertension (PAH). The report excludes drugs used in the treatment of ocular hypertension. The market size includes both branded and generic drugs.
The report highlights the current and future market potential of antihypertensive drugs and provides a detailed analysis of the competitive environment, regulatory scenario, patent analysis, pipeline analysis, drivers, restraints, opportunities and trends in the market. The report also covers market projections through 2023, as well as market shares for key market players.
The report details market shares of antihypertensive drugs based on drug class and geography. Based on drug class, the market is segmented into ACE inhibitors (angiotensin-converting enzyme inhibitors), ARBs (angiotensin II receptor blockers), beta blockers, calcium channel blockers, diuretics, combination drugs, and others (a segment that includes direct renin inhibitors, alpha blockers, PDE-5 inhibitors, stimulators of soluble guanylate cyclase, endothelin receptor antagonists, vasodilators, and prostacyclin receptors).
The market is segmented by geography into the following regions: North America, Europe, Asia-Pacific, South America, and the Middle East and Africa. The report presents detailed analyses of major countries such as the U.S., Canada, Mexico, Germany, the U.K. France, Spain, Italy, Japan, China and India. For market estimates, data is provided for 2017 as the base year, with forecasts for 2018 through 2023. Estimated values are based on drug manufacturers’ total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.
Report Includes:
- 67 tables
- Country specific data and analysis for France, Germany, Italy, U.K., Spain, Russia, India, China, Japan, United States, Canada, Middle East and Africa
- A brief study of current and future market potential of antihypertensive drugs along with a detailed analysis of the competitive environment
- Exposure to the industry driven underlying markets, government regulations, and technology updates
- Coverage of regulatory dynamics, pipeline analysis, patent analysis, and market drivers, restrains, and opportunities
- Company profiles of major manufacturers, suppliers, and supply chain participants, including Allergan Plc, Boehringer Ingelheim GMBH, Johnson & Johnson, Daiichi Sankyo Co. Ltd, Pfizer Inc. and Novartis AG
CHAPTER 1 INTRODUCTION
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analysts’ Credentials
BCC Custom Research
Related BCC Research Reports
CHAPTER 2 SUMMARY AND HIGHLIGHTS
CHAPTER 3 MARKET AND TECHNOLOGY BACKGROUND
Hypertension
Pathophysiology and Pathogenesis
Classification
Prevalence of Hypertension
Antihypertensive Drugs
Commonly Prescribed Antihypertensive Drugs
Side Effects of Antihypertensive Drugs
Contraindications of Major Antihypertensive Drugs
Resistant Hypertension
CHAPTER 4 MARKET DYNAMICS
Growth Drivers
Increasing Prevalence of Hypertension
Rising Geriatric Population and Government Assistance for Prescription Drugs
Sedentary Lifestyle: Contributing Significantly toward High Risk of Hypertension
Improved Awareness of Hypertension: Earlier Diagnosis and Treatment
Market Restraints
Patent Expirations of Branded Drugs
Drug Development Process: High Cost and Pricing Pressures
Market Opportunities
Patent Expiration: Growth Opportunities for Generic Players
Unmet Needs in Low- and Middle-Income Countries
CHAPTER 5 MARKET BREAKDOWN BY DRUG CLASS
Global Antihypertensive Drug Market
Angiotensin-Converting Enzyme (ACE) Inhibitors
Market Size and Forecast
Market Analysis
Angiotensin II Receptor Blockers
Market Size and Forecast
Market Analysis
Beta Blockers
Market Size and Forecast
Market Analysis
Calcium Channel Blockers
Market Size and Forecast
Market Analysis
Diuretics
Market Size and Forecast
Market Analysis
Combination Drug
Market Size and Forecast
Market Analysis
Others
Market Size and Forecast
Market Analysis
CHAPTER 6 MARKET BREAKDOWN BY REGION
Global Market for Antihypertensives by Region
North America
United States
Canada
Mexico
Europe
Germany
France
&^%$fghj U.K.
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Rest of Asia-Pacific
South America
Market Size and Forecast
Market Analysis
Middle East and Africa
Market Size and Forecast
Market Analysis
CHAPTER 7 REGULATORY ENVIRONMENT
Regulations in the U.S.
New Drug Approvals
The FDA Modernization Act of 1997
Fast-Track Status
Special Protocol Assessments
Medicare
Principles for Clinical Evaluation of New Antihypertensive Drugs
Hypertension Guidelines in the U.S.
Regulations in Europe
Hypertension Guidelines in Europe
Pricing and Reimbursement
Regulations in Asia-Pacific
Regulations in Japan
Regulations in China
Regulations in India
CHAPTER 8 PATENT ANALYSIS
Patent Length and Market Exclusivity
CHAPTER 9 PIPELINE ANALYSIS
Overview of the Drug Development Process
Pipeline Analysis of Antihypertensive Drugs
Antihypertensive Drugs in Phase I Clinical Trials
Antihypertensive Drugs in Phase II Clinical Trials
Antihypertensive Drugs in Phase III Clinical Trials
Late-Stage Pipeline Drugs
CHAPTER 10 COMPETITIVE LANDSCAPE
Global Company Share Analysis
Mergers and Acquisitions
Agreements, Collaborations, and Partnerships
Impact of Generic Antihypertensives on the Market
CHAPTER 11 COMPANY PROFILES
&^%$fghj ALLERGAN PLC
Company Overview
Business Performance
Products Offered
Developments and Strategies
&^%$fghj ASTELLAS PHARMA INC.
Company Overview
Products Offered
Developments and Strategies
&^%$fghj ARBOR PHARMACEUTICALS LLC
Company Overview
Products Offered
&^%$fghj ASTRAZENECA PLC
Company Overview
Business Performance
AstraZeneca plc Business Segment Revenue
AstraZeneca Plc Revenue by Region Segment
Product Portfolio
Developments and Strategies
&^%$fghj BAYER AG
Company Overview
Business Performance
Products Offered
Developments and Strategies
&^%$fghj BOEHRINGER INGELHEIM GMBH
Company Overview
Business Performance
Products Offered
Developments and Strategies
&^%$fghj DAIICHI SANKYO CO. LTD.
Company Overview
Business Performance
Products Offered
Developments and Strategies
&^%$fghj ELI LILLY AND CO.
Company Overview
Products Offered
Developments and Strategies
&^%$fghj GILEAD SCIENCES INC.
Company Overview
Business Performance
Products Offered
Developments and Strategies
&^%$fghj GLAXOSMITHKLINE PLC
Company Overview
Products Offered
Developments and Strategies
&^%$fghj HIKMA PHARMACEUTICALS PLC
Company Overview
Products Offered
&^%$fghj JOHNSON & JOHNSON
Company Overview
Business Performance
Product Portfolio
Developments and Strategies
&^%$fghj LUPIN LTD.
Company Overview
Product Portfolio
&^%$fghj MERCK & CO. INC.
Company Overview
Products Offered
Developments and Strategies
&^%$fghj NOVARTIS AG
Company Overview
Business Performance
Products Offered
Developments and Strategies
&^%$fghj PFIZER INC.
Company Overview
Business Performance
Products Offered
Developments and Strategies
&^%$fghj SANOFI
Company Overview
Business Performance
Products Offered
Developments and Strategies
&^%$fghj TAKEDA PHARMACEUTICAL CO. LTD.
Company Overview
Product Portfolio
&^%$fghj TEVA PHARMACEUTICAL INDUSTRIES LTD.
Company Overview
Products Offered
&^%$fghj UNITED THERAPEUTICS CORP.
Company Overview
Business Performance
Products Offered
Developments and Strategies
CHAPTER 12 APPENDIX: ACRONYMS
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analysts’ Credentials
BCC Custom Research
Related BCC Research Reports
CHAPTER 2 SUMMARY AND HIGHLIGHTS
CHAPTER 3 MARKET AND TECHNOLOGY BACKGROUND
Hypertension
Pathophysiology and Pathogenesis
Classification
Prevalence of Hypertension
Antihypertensive Drugs
Commonly Prescribed Antihypertensive Drugs
Side Effects of Antihypertensive Drugs
Contraindications of Major Antihypertensive Drugs
Resistant Hypertension
CHAPTER 4 MARKET DYNAMICS
Growth Drivers
Increasing Prevalence of Hypertension
Rising Geriatric Population and Government Assistance for Prescription Drugs
Sedentary Lifestyle: Contributing Significantly toward High Risk of Hypertension
Improved Awareness of Hypertension: Earlier Diagnosis and Treatment
Market Restraints
Patent Expirations of Branded Drugs
Drug Development Process: High Cost and Pricing Pressures
Market Opportunities
Patent Expiration: Growth Opportunities for Generic Players
Unmet Needs in Low- and Middle-Income Countries
CHAPTER 5 MARKET BREAKDOWN BY DRUG CLASS
Global Antihypertensive Drug Market
Angiotensin-Converting Enzyme (ACE) Inhibitors
Market Size and Forecast
Market Analysis
Angiotensin II Receptor Blockers
Market Size and Forecast
Market Analysis
Beta Blockers
Market Size and Forecast
Market Analysis
Calcium Channel Blockers
Market Size and Forecast
Market Analysis
Diuretics
Market Size and Forecast
Market Analysis
Combination Drug
Market Size and Forecast
Market Analysis
Others
Market Size and Forecast
Market Analysis
CHAPTER 6 MARKET BREAKDOWN BY REGION
Global Market for Antihypertensives by Region
North America
United States
Canada
Mexico
Europe
Germany
France
&^%$fghj U.K.
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Rest of Asia-Pacific
South America
Market Size and Forecast
Market Analysis
Middle East and Africa
Market Size and Forecast
Market Analysis
CHAPTER 7 REGULATORY ENVIRONMENT
Regulations in the U.S.
New Drug Approvals
The FDA Modernization Act of 1997
Fast-Track Status
Special Protocol Assessments
Medicare
Principles for Clinical Evaluation of New Antihypertensive Drugs
Hypertension Guidelines in the U.S.
Regulations in Europe
Hypertension Guidelines in Europe
Pricing and Reimbursement
Regulations in Asia-Pacific
Regulations in Japan
Regulations in China
Regulations in India
CHAPTER 8 PATENT ANALYSIS
Patent Length and Market Exclusivity
CHAPTER 9 PIPELINE ANALYSIS
Overview of the Drug Development Process
Pipeline Analysis of Antihypertensive Drugs
Antihypertensive Drugs in Phase I Clinical Trials
Antihypertensive Drugs in Phase II Clinical Trials
Antihypertensive Drugs in Phase III Clinical Trials
Late-Stage Pipeline Drugs
CHAPTER 10 COMPETITIVE LANDSCAPE
Global Company Share Analysis
Mergers and Acquisitions
Agreements, Collaborations, and Partnerships
Impact of Generic Antihypertensives on the Market
CHAPTER 11 COMPANY PROFILES
&^%$fghj ALLERGAN PLC
Company Overview
Business Performance
Products Offered
Developments and Strategies
&^%$fghj ASTELLAS PHARMA INC.
Company Overview
Products Offered
Developments and Strategies
&^%$fghj ARBOR PHARMACEUTICALS LLC
Company Overview
Products Offered
&^%$fghj ASTRAZENECA PLC
Company Overview
Business Performance
AstraZeneca plc Business Segment Revenue
AstraZeneca Plc Revenue by Region Segment
Product Portfolio
Developments and Strategies
&^%$fghj BAYER AG
Company Overview
Business Performance
Products Offered
Developments and Strategies
&^%$fghj BOEHRINGER INGELHEIM GMBH
Company Overview
Business Performance
Products Offered
Developments and Strategies
&^%$fghj DAIICHI SANKYO CO. LTD.
Company Overview
Business Performance
Products Offered
Developments and Strategies
&^%$fghj ELI LILLY AND CO.
Company Overview
Products Offered
Developments and Strategies
&^%$fghj GILEAD SCIENCES INC.
Company Overview
Business Performance
Products Offered
Developments and Strategies
&^%$fghj GLAXOSMITHKLINE PLC
Company Overview
Products Offered
Developments and Strategies
&^%$fghj HIKMA PHARMACEUTICALS PLC
Company Overview
Products Offered
&^%$fghj JOHNSON & JOHNSON
Company Overview
Business Performance
Product Portfolio
Developments and Strategies
&^%$fghj LUPIN LTD.
Company Overview
Product Portfolio
&^%$fghj MERCK & CO. INC.
Company Overview
Products Offered
Developments and Strategies
&^%$fghj NOVARTIS AG
Company Overview
Business Performance
Products Offered
Developments and Strategies
&^%$fghj PFIZER INC.
Company Overview
Business Performance
Products Offered
Developments and Strategies
&^%$fghj SANOFI
Company Overview
Business Performance
Products Offered
Developments and Strategies
&^%$fghj TAKEDA PHARMACEUTICAL CO. LTD.
Company Overview
Product Portfolio
&^%$fghj TEVA PHARMACEUTICAL INDUSTRIES LTD.
Company Overview
Products Offered
&^%$fghj UNITED THERAPEUTICS CORP.
Company Overview
Business Performance
Products Offered
Developments and Strategies
CHAPTER 12 APPENDIX: ACRONYMS
LIST OF TABLES
Summary Table: Global Market for Antihypertensive Drugs, by Drug Class, Through 2023
Table 1: Classification of Hypertension or Blood Pressure
Table 2: Global Prevalence of Hypertension with Population Aged 18 Years or Older, by Country, 2015
Table 3: Commonly Prescribed Antihypertensive Drugs
Table 4: Side Effects with Different Classes of Antihypertensive Drugs
Table 5: Contraindications of Major Antihypertensive Drugs
Table 6: Prevalence of High Blood Pressure, by Gender and Age Group, U.S., 2016
Table 7: Prevalence Rates of Obesity for Male and Female in Australia, 1995-2015
Table 8: Patent Expiration Dates for Antihypertensive Drugs, 2016-2018*
Table 9: Global Market for Antihypertensive Drugs, by Drug Class, Through 2023
Table 10: Global Market for Angiotensin-Converting Enzyme (ACE) Inhibitors, by Region, Through 2023
Table 11: ACE Inhibitors Drug, Branded/Generic FDA Approval
Table 12: Global Market for Angiotensin II Receptor Blockers (ARBs), by Region, Through 2023
Table 13: Global Market for Beta Blocker Drugs, by Region, Through 2023
Table 14: Global Market for Calcium Channel Blocker Drugs, by Region, Through 2023
Table 15: Global Market for Diuretics Drugs, by Region, Through 2023
Table 16: Global Market for Combination Drugs, by Region, Through 2023
Table 17: Commonly Prescribed Combinations of Antihypertensive Drugs
Table 18: Global Market for Other Antihypertensive Drugs, by Region, Through 2023
Table 19: Commonly Prescribed Types of Other Antihypertensive Drugs
Table 20: Global Market for Antihypertensive Drugs, by Region, Through 2023
Table 21: North American Market for Antihypertensive Drugs, by Drug Class, Through 2023
Table 22: North American Market for Antihypertensive Drugs, by Country, Through 2023
Table 23: Total Number of High Blood Pressure Patients in Canada, by Age Group, 2016 and 2017
Table 24: European Market for Antihypertensive Drugs, by Drug Class, Through 2023
Table 25: European Market for Antihypertensive Drugs, by Country, Through 2023
Table 26: Asia-Pacific Market for Antihypertensive Drugs, by Drug Class, Through 2023
Table 27: Asia-Pacific Market for Antihypertensive Drugs, by Country, Through 2023
Table 28: South American Market for Antihypertensive Drugs, by Drug Class, Through 2023
Table 29: Middle Eastern and African Market for Antihypertensive Drugs, by Drug Class, Through 2023
Table 30: Arbor Pharmaceuticals LLC: Antihypertensives Patent Exclusivity
Table 31: Allergan Plc: Antihypertensives Patent Exclusivity
Table 32: Chiesi USA Inc.: Antihypertensives Patent Exclusivity
Table 33: Eli Lilly and Co.: Antihypertensives Patent Exclusivity
Table 34: Gilead Sciences Inc.: Antihypertensives Patent Exclusivity
Table 35: GlaxoSmithKline plc: Antihypertensives Patent Exclusivity
Table 36: Novartis AG: Antihypertensives Patent Exclusivity
Table 37: Noden Pharma DAC: Antihypertensives Patent Exclusivity
Table 38: Johnson & Johnson: Antihypertensives Patent Exclusivity
Table 39: United Therapeutics Corp.: Antihypertensives Patents Exclusivity
Table 40: Other Applicants: Antihypertensives Patent Exclusivity
Table 41: Exclusivity Expiration of Antihypertensive Drugs
Table 42: Preclinical & Phase I Pipeline of Antihypertensive Drugs
Table 43: Phase II Pipeline of Antihypertensive Drugs
Table 44: Phase III Pipeline of Antihypertensive Drugs
Table 45: Generic Launches in the Antihypertensive Market, 2015-2018
Table 46: Allergan Plc: Antihypertensive Drugs Product Portfolio
Table 47: Astellas Pharma Inc.: Antihypertensive Drugs Product Portfolio
Table 48: Arbor Pharmaceutical LLC.: Antihypertensive Drugs Product Portfolio
Table 49: AstraZeneca Plc: Antihypertensive Drugs Product Portfolio
Table 50: Bayer AG: Antihypertensive Drugs Product Portfolio
Table 51: Boehringer Ingelheim GmbH: Antihypertensive Drugs Product Portfolio
Table 52: Daiichi Sankyo Co. Ltd.: Antihypertensive Drugs Product Portfolio
Table 53: Eli Lilly and Co.: Antihypertensive Drugs Product Portfolio
Table 54: Gilead Science Inc.: Antihypertensive Drugs Product Portfolio
Table 55: GlaxoSmithKline Plc: Antihypertensive Drugs Product Portfolio
Table 56: Hikma Pharmaceuticals Plc: Antihypertensive Drugs Product Portfolio
Table 57: Johnson & Johnson: Antihypertensive Drugs Product Portfolio
Table 58: Lupin Ltd.: Antihypertensive Drugs Product Portfolio
Table 59: Merck & Co. Inc.: Antihypertensive Drugs Product Portfolio
Table 60: Novartis AG: Antihypertensive Drugs Product Portfolio
Table 61: Pfizer Inc.: Antihypertensive Drugs Product Portfolio
Table 62: Sanofi: Antihypertensive Drugs Product Portfolio
Table 63: Takeda Pharmaceutical.: Antihypertensive Drugs Product Portfolio
Table 64: Teva Pharmaceutical Industries Ltd.: Antihypertensive Drugs Product Portfolio
Table 65: United Therapeutics Corp.: Antihypertensive Drugs Product Portfolio
Table 66: Acronyms Used in This Report
Summary Table: Global Market for Antihypertensive Drugs, by Drug Class, Through 2023
Table 1: Classification of Hypertension or Blood Pressure
Table 2: Global Prevalence of Hypertension with Population Aged 18 Years or Older, by Country, 2015
Table 3: Commonly Prescribed Antihypertensive Drugs
Table 4: Side Effects with Different Classes of Antihypertensive Drugs
Table 5: Contraindications of Major Antihypertensive Drugs
Table 6: Prevalence of High Blood Pressure, by Gender and Age Group, U.S., 2016
Table 7: Prevalence Rates of Obesity for Male and Female in Australia, 1995-2015
Table 8: Patent Expiration Dates for Antihypertensive Drugs, 2016-2018*
Table 9: Global Market for Antihypertensive Drugs, by Drug Class, Through 2023
Table 10: Global Market for Angiotensin-Converting Enzyme (ACE) Inhibitors, by Region, Through 2023
Table 11: ACE Inhibitors Drug, Branded/Generic FDA Approval
Table 12: Global Market for Angiotensin II Receptor Blockers (ARBs), by Region, Through 2023
Table 13: Global Market for Beta Blocker Drugs, by Region, Through 2023
Table 14: Global Market for Calcium Channel Blocker Drugs, by Region, Through 2023
Table 15: Global Market for Diuretics Drugs, by Region, Through 2023
Table 16: Global Market for Combination Drugs, by Region, Through 2023
Table 17: Commonly Prescribed Combinations of Antihypertensive Drugs
Table 18: Global Market for Other Antihypertensive Drugs, by Region, Through 2023
Table 19: Commonly Prescribed Types of Other Antihypertensive Drugs
Table 20: Global Market for Antihypertensive Drugs, by Region, Through 2023
Table 21: North American Market for Antihypertensive Drugs, by Drug Class, Through 2023
Table 22: North American Market for Antihypertensive Drugs, by Country, Through 2023
Table 23: Total Number of High Blood Pressure Patients in Canada, by Age Group, 2016 and 2017
Table 24: European Market for Antihypertensive Drugs, by Drug Class, Through 2023
Table 25: European Market for Antihypertensive Drugs, by Country, Through 2023
Table 26: Asia-Pacific Market for Antihypertensive Drugs, by Drug Class, Through 2023
Table 27: Asia-Pacific Market for Antihypertensive Drugs, by Country, Through 2023
Table 28: South American Market for Antihypertensive Drugs, by Drug Class, Through 2023
Table 29: Middle Eastern and African Market for Antihypertensive Drugs, by Drug Class, Through 2023
Table 30: Arbor Pharmaceuticals LLC: Antihypertensives Patent Exclusivity
Table 31: Allergan Plc: Antihypertensives Patent Exclusivity
Table 32: Chiesi USA Inc.: Antihypertensives Patent Exclusivity
Table 33: Eli Lilly and Co.: Antihypertensives Patent Exclusivity
Table 34: Gilead Sciences Inc.: Antihypertensives Patent Exclusivity
Table 35: GlaxoSmithKline plc: Antihypertensives Patent Exclusivity
Table 36: Novartis AG: Antihypertensives Patent Exclusivity
Table 37: Noden Pharma DAC: Antihypertensives Patent Exclusivity
Table 38: Johnson & Johnson: Antihypertensives Patent Exclusivity
Table 39: United Therapeutics Corp.: Antihypertensives Patents Exclusivity
Table 40: Other Applicants: Antihypertensives Patent Exclusivity
Table 41: Exclusivity Expiration of Antihypertensive Drugs
Table 42: Preclinical & Phase I Pipeline of Antihypertensive Drugs
Table 43: Phase II Pipeline of Antihypertensive Drugs
Table 44: Phase III Pipeline of Antihypertensive Drugs
Table 45: Generic Launches in the Antihypertensive Market, 2015-2018
Table 46: Allergan Plc: Antihypertensive Drugs Product Portfolio
Table 47: Astellas Pharma Inc.: Antihypertensive Drugs Product Portfolio
Table 48: Arbor Pharmaceutical LLC.: Antihypertensive Drugs Product Portfolio
Table 49: AstraZeneca Plc: Antihypertensive Drugs Product Portfolio
Table 50: Bayer AG: Antihypertensive Drugs Product Portfolio
Table 51: Boehringer Ingelheim GmbH: Antihypertensive Drugs Product Portfolio
Table 52: Daiichi Sankyo Co. Ltd.: Antihypertensive Drugs Product Portfolio
Table 53: Eli Lilly and Co.: Antihypertensive Drugs Product Portfolio
Table 54: Gilead Science Inc.: Antihypertensive Drugs Product Portfolio
Table 55: GlaxoSmithKline Plc: Antihypertensive Drugs Product Portfolio
Table 56: Hikma Pharmaceuticals Plc: Antihypertensive Drugs Product Portfolio
Table 57: Johnson & Johnson: Antihypertensive Drugs Product Portfolio
Table 58: Lupin Ltd.: Antihypertensive Drugs Product Portfolio
Table 59: Merck & Co. Inc.: Antihypertensive Drugs Product Portfolio
Table 60: Novartis AG: Antihypertensive Drugs Product Portfolio
Table 61: Pfizer Inc.: Antihypertensive Drugs Product Portfolio
Table 62: Sanofi: Antihypertensive Drugs Product Portfolio
Table 63: Takeda Pharmaceutical.: Antihypertensive Drugs Product Portfolio
Table 64: Teva Pharmaceutical Industries Ltd.: Antihypertensive Drugs Product Portfolio
Table 65: United Therapeutics Corp.: Antihypertensive Drugs Product Portfolio
Table 66: Acronyms Used in This Report
LIST OF FIGURES
Summary Figure: Global Market Share for Antihypertensive Drugs, by Drug Class, 2017
Figure 1: Prevalence of Hypertension Among U.S. Adults Aged 18 and Older, by Sex and Age, 2016
Figure 2: Prevalence Rates for Adult Obesity, by Country, 2016
Figure 3: Diovan/Co-Diovan Revenue, 2013-2017
Figure 4: Global Market Share for Antihypertensive Drugs, by Drug Class, 2017
Figure 5: Global Market for Angiotensin-Converting Enzyme (ACE) Inhibitors, 2017-2023
Figure 6: Global Market for Angiotensin-Converting Enzyme (ACE) Inhibitors, by Region, 2017-2023
Figure 7: Global Market for Angiotensin II Receptor Blockers (ARBs), 2017-2023
Figure 8: Global Market for Angiotensin II Receptor Blockers (ARBs), by Region, 2017-2023
Figure 9: Leading ARBs Drug Prescriptions in the U.S., 2016
Figure 10: Global Market for Beta Blocker Drugs, 2017-2023
Figure 11: Global Market for Beta Blocker Drugs, by Region, 2017-2023
Figure 12: Global Market for Calcium Channel Blocker Drugs, 2017-2023
Figure 13: Global Market for Calcium Channel Blocker Drugs, by Region, 2017-2023
Figure 14: Global Market for Diuretics Drugs, 2017-2023
Figure 15: Global Market for Diuretics Drugs, by Region, 2017-2023
Figure 16: Global Market for Combination Drugs, 2017-2023
Figure 17: Global Market for Combination Drugs, by Region, 2017-2023
Figure 18: Global Market for Other Antihypertensive Drugs, 2017-2023
Figure 19: Global Market for Other Antihypertensive Drugs, by Region, 2017-2023
Figure 20: Global Market Share for Antihypertensive Drugs, by Region, 2017
Figure 21: North American Market Share for Antihypertensive Drugs, by Drug Class, 2017
Figure 22: North American Market Share for Antihypertensive Drugs, by Country, 2017
Figure 23: U.S. Market for Antihypertensive Drugs, 2017-2023
Figure 24: Canadian Market for Antihypertensive Drugs, 2017-2023
Figure 25: Mexican Market for Antihypertensive Drugs, 2017-2023
Figure 26: European Market Share for Antihypertensive Drugs, by Drug Class, 2017
Figure 27: European Market Share for Antihypertensive Drugs, by Country, 2017
Figure 28: German Market for Antihypertensive Drugs, 2017-2023
Figure 29: French Market for Antihypertensive Drugs, 2017-2023
Figure 30: U.K. Market for Antihypertensive Drugs, 2017-2023
Figure 31: Italian Market for Antihypertensive Drugs, 2017-2023
Figure 32: Spanish Market for Antihypertensive Drugs, 2017-2023
Figure 33: Rest of Europe Market for Antihypertensive Drugs, 2017-2023
Figure 34: Asia-Pacific Market Share for Antihypertensive Drugs, by Drug Class, 2017
Figure 35: Asia-Pacific Market Share for Antihypertensive Drugs, by Country, 2017
Figure 36: Japanese Market for Antihypertensive Drugs, 2017-2023
Figure 37: Chinese Market for Antihypertensive Drugs, 2017-2023
Figure 38: Indian Market for Antihypertensive Drugs, 2017-2023
Figure 39: Rest of Asia-Pacific Market for Antihypertensive Drugs, 2017-2023
Figure 40: South American Market for Antihypertensive Drugs, 2017-2023
Figure 41: South American Market Share for Antihypertensive Drugs, by Drug Class, 2017
Figure 42: Middle Eastern and African Market for Antihypertensive Drugs, 2017-2023
Figure 43: Middle East and African Market Share for Antihypertensive Drugs, by Drug Class, 2017
Figure 44: China CFDA Drug Regulatory Approval Process
Figure 45: Global Antihypertensive Drug Market Share, by Manufacturer, 2017
Figure 46: Novartis AG: Sales Revenue for Co-Diovan/Diovan HCT, 2014-2017
Figure 47: Allergan Plc: Annual Revenue, 2013-2017
Figure 48: Allergan Plc: Revenue Share, by Business Unit, 2017
Figure 49: AstraZeneca Plc: Annual Revenue, 2013-2017
Figure 50: AstraZeneca Plc: Revenue Share, by Business Unit, 2017
Figure 51: AstraZeneca Plc: Revenue Share, by Region, 2017
Figure 52: Bayer AG: Annual Revenue, 2013-2017
Figure 53: Bayer AG: Revenue Share, by Region, 2017
Figure 54: Boehringer Ingelheim GmbH: Annual Revenue, 2013-2017
Figure 55: Boehringer Ingelheim GmbH: Revenue Share, by Region, 2017
Figure 56: Daiichi Sankyo Co. Ltd.: Annual Revenue, 2015-2017
Figure 57: Gilead Sciences Inc.: Annual Revenue, 2014-2017
Figure 58: Johnson & Johnson: Annual Revenue, 2013-2017
Figure 59: Johnson & Johnson: Revenue Share, by Region, 2017
Figure 60: Johnson & Johnson: Revenue Share, by Business Unit, 2017
Figure 61: Novartis AG.: Annual Revenue, 2013-2017
Figure 62: Novartis AG: Revenue Share, by Region, 2017
Figure 63: Novartis AG: Revenue Share, by Business Segment, 2017
Figure 64: Pfizer Inc.: Annual Revenue, 2013-2017
Figure 65: Pfizer Inc.: Revenue Share, by Region, 2017
Figure 66: Pfizer Inc.: Revenue Share, by Business Segment, 2017
Figure 67: Sanofi.: Annual Revenue, 2013-2017
Figure 68: Sanofi: Revenue Share, by Region, 2017
Figure 69: United Therapeutics Corp: Annual Revenue, 2015-2017
Summary Figure: Global Market Share for Antihypertensive Drugs, by Drug Class, 2017
Figure 1: Prevalence of Hypertension Among U.S. Adults Aged 18 and Older, by Sex and Age, 2016
Figure 2: Prevalence Rates for Adult Obesity, by Country, 2016
Figure 3: Diovan/Co-Diovan Revenue, 2013-2017
Figure 4: Global Market Share for Antihypertensive Drugs, by Drug Class, 2017
Figure 5: Global Market for Angiotensin-Converting Enzyme (ACE) Inhibitors, 2017-2023
Figure 6: Global Market for Angiotensin-Converting Enzyme (ACE) Inhibitors, by Region, 2017-2023
Figure 7: Global Market for Angiotensin II Receptor Blockers (ARBs), 2017-2023
Figure 8: Global Market for Angiotensin II Receptor Blockers (ARBs), by Region, 2017-2023
Figure 9: Leading ARBs Drug Prescriptions in the U.S., 2016
Figure 10: Global Market for Beta Blocker Drugs, 2017-2023
Figure 11: Global Market for Beta Blocker Drugs, by Region, 2017-2023
Figure 12: Global Market for Calcium Channel Blocker Drugs, 2017-2023
Figure 13: Global Market for Calcium Channel Blocker Drugs, by Region, 2017-2023
Figure 14: Global Market for Diuretics Drugs, 2017-2023
Figure 15: Global Market for Diuretics Drugs, by Region, 2017-2023
Figure 16: Global Market for Combination Drugs, 2017-2023
Figure 17: Global Market for Combination Drugs, by Region, 2017-2023
Figure 18: Global Market for Other Antihypertensive Drugs, 2017-2023
Figure 19: Global Market for Other Antihypertensive Drugs, by Region, 2017-2023
Figure 20: Global Market Share for Antihypertensive Drugs, by Region, 2017
Figure 21: North American Market Share for Antihypertensive Drugs, by Drug Class, 2017
Figure 22: North American Market Share for Antihypertensive Drugs, by Country, 2017
Figure 23: U.S. Market for Antihypertensive Drugs, 2017-2023
Figure 24: Canadian Market for Antihypertensive Drugs, 2017-2023
Figure 25: Mexican Market for Antihypertensive Drugs, 2017-2023
Figure 26: European Market Share for Antihypertensive Drugs, by Drug Class, 2017
Figure 27: European Market Share for Antihypertensive Drugs, by Country, 2017
Figure 28: German Market for Antihypertensive Drugs, 2017-2023
Figure 29: French Market for Antihypertensive Drugs, 2017-2023
Figure 30: U.K. Market for Antihypertensive Drugs, 2017-2023
Figure 31: Italian Market for Antihypertensive Drugs, 2017-2023
Figure 32: Spanish Market for Antihypertensive Drugs, 2017-2023
Figure 33: Rest of Europe Market for Antihypertensive Drugs, 2017-2023
Figure 34: Asia-Pacific Market Share for Antihypertensive Drugs, by Drug Class, 2017
Figure 35: Asia-Pacific Market Share for Antihypertensive Drugs, by Country, 2017
Figure 36: Japanese Market for Antihypertensive Drugs, 2017-2023
Figure 37: Chinese Market for Antihypertensive Drugs, 2017-2023
Figure 38: Indian Market for Antihypertensive Drugs, 2017-2023
Figure 39: Rest of Asia-Pacific Market for Antihypertensive Drugs, 2017-2023
Figure 40: South American Market for Antihypertensive Drugs, 2017-2023
Figure 41: South American Market Share for Antihypertensive Drugs, by Drug Class, 2017
Figure 42: Middle Eastern and African Market for Antihypertensive Drugs, 2017-2023
Figure 43: Middle East and African Market Share for Antihypertensive Drugs, by Drug Class, 2017
Figure 44: China CFDA Drug Regulatory Approval Process
Figure 45: Global Antihypertensive Drug Market Share, by Manufacturer, 2017
Figure 46: Novartis AG: Sales Revenue for Co-Diovan/Diovan HCT, 2014-2017
Figure 47: Allergan Plc: Annual Revenue, 2013-2017
Figure 48: Allergan Plc: Revenue Share, by Business Unit, 2017
Figure 49: AstraZeneca Plc: Annual Revenue, 2013-2017
Figure 50: AstraZeneca Plc: Revenue Share, by Business Unit, 2017
Figure 51: AstraZeneca Plc: Revenue Share, by Region, 2017
Figure 52: Bayer AG: Annual Revenue, 2013-2017
Figure 53: Bayer AG: Revenue Share, by Region, 2017
Figure 54: Boehringer Ingelheim GmbH: Annual Revenue, 2013-2017
Figure 55: Boehringer Ingelheim GmbH: Revenue Share, by Region, 2017
Figure 56: Daiichi Sankyo Co. Ltd.: Annual Revenue, 2015-2017
Figure 57: Gilead Sciences Inc.: Annual Revenue, 2014-2017
Figure 58: Johnson & Johnson: Annual Revenue, 2013-2017
Figure 59: Johnson & Johnson: Revenue Share, by Region, 2017
Figure 60: Johnson & Johnson: Revenue Share, by Business Unit, 2017
Figure 61: Novartis AG.: Annual Revenue, 2013-2017
Figure 62: Novartis AG: Revenue Share, by Region, 2017
Figure 63: Novartis AG: Revenue Share, by Business Segment, 2017
Figure 64: Pfizer Inc.: Annual Revenue, 2013-2017
Figure 65: Pfizer Inc.: Revenue Share, by Region, 2017
Figure 66: Pfizer Inc.: Revenue Share, by Business Segment, 2017
Figure 67: Sanofi.: Annual Revenue, 2013-2017
Figure 68: Sanofi: Revenue Share, by Region, 2017
Figure 69: United Therapeutics Corp: Annual Revenue, 2015-2017
